ERNA
Ernexa Therapeutics Inc.
There isn't enough reported data to score ERNA yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ERNA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ERNA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ERNA PE Valuation
ERNA has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ERNA Forward outlook
There aren't enough analyst estimates for ERNA to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ERNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$4,308.75 | +$13,541.25 |
| Q2 2022 | -$16,125.00 | -$3,525.00 |
| Q1 2022 | -$17,475.00 | +$3,675.00 |
| Q4 2021 | -$21,000.00 | +$1,650.00 |
| Q3 2021 | -$17,850.00 | +$13,200.00 |
| Q2 2021 | -$12,600.00 | +$12,750.00 |
| Q1 2021 | -$21,150.00 | -$5,700.00 |
| Q4 2020 | -$22,650.00 | -$11,850.00 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 172% for ERNA versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ERNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $1K | -94% |
| Q3 2024 | $487K | +855% |
| Q4 2020 | $1.2M | -77% |
ERNA's revenue has slid since its 2019 peak: $1,000 last quarter, down 94% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -269700% | -235788 points |
| Q3 2024 | -464% | +10330 points |
| Q2 2024 | -10491% | N/A |
| Q1 2024 | -12313% | N/A |
| Q4 2023 | -33912% | N/A |
| Q3 2023 | -10794% | N/A |
| Q4 2020 | -63% | -39 points |
| Q3 2020 | -96% | N/A |
ERNA's operating margin was −269700% last quarter, down 235788 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ERNA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ERNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.2M | +$2.4M |
| Q4 2024 | -$3.5M | +$1.1M |
| Q3 2024 | -$6.3M | -$478K |
| Q2 2024 | -$2.5M | +$1.4M |
| Q1 2024 | -$3.8M | +$2.2M |
| Q4 2023 | -$4.7M | +$776K |
| Q3 2023 | -$5.8M | +$333K |
| Q2 2023 | -$3.9M | +$308K |
ERNA has the stronger cash trend. Its trailing FCF is up 35% versus its history, compared with UNH at up 5.2%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ERNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | 0% | -- |
| 3 years | +7298% | +14.2K shares |
ERNA has 14,427 diluted shares, about the same as a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ERNA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ERNA Net Leverage
ERNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ERNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.0 | Oversold |
| Stochastic | 2.9 | Oversold |
ERNA's weekly RSI is 30 (oversold) and its Stochastic is 3 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ERNA PE vs Healthcare Sector
ERNA has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ERNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.33 | 23% below |
| 20 week MA | $3.74 | 52% below |
| 50 week MA | $10.2 | 82% below |
| 100 week MA | $40.6 | 96% below |
| 200 week MA | $416.1 | 100% below |
ERNA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ERNA on trend strength, trading above more of its moving averages.
ERNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33,600.0 | $32,250.0 | -4% |
| 2021 | $32,250.0 | $37,425.0 | +16% |
| 2022 | $37,425.0 | $1,286.3 | -97% |
| 2023 | $1,286.3 | $675.0 | -48% |
| 2024 | $675.0 | $95.0 | -86% |
| 2025 | $95.0 | $30.3 | -68% |
| 2026 YTD | $30.3 | $1.79 | -94% |
ERNA has finished four years in a row lower, and it's down 94% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ERNA on returns for 2026, with the stronger performance.